These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12646969)

  • 21. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2].
    Tada Y; Nagasawa K
    Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs.
    Tanaka A; Araki H; Komoike Y; Hase S; Takeuchi K
    J Physiol Paris; 2001; 95(1-6):21-7. PubMed ID: 11595414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology and clinical action of COX-2 selective NSAIDs.
    Bovill JG
    Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852
    [No Abstract]   [Full Text] [Related]  

  • 25. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
    Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.
    Buttgereit F; Burmester GR; Simon LS
    Am J Med; 2001 Feb; 110 Suppl 3A():13S-9S. PubMed ID: 11173045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution.
    Noroian G; Clive D
    Drug Saf; 2002; 25(3):165-72. PubMed ID: 11945113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal effects of cyclooxygyenase-2-selective inhibitors.
    Brater DC
    J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S15-20; discussion S21-3. PubMed ID: 11992745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications.
    Meagher EA
    Drug Saf; 2003; 26(13):913-24. PubMed ID: 14583067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
    Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
    J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory drugs and their mechanism of action.
    Vane JR; Botting RM
    Inflamm Res; 1998 Oct; 47 Suppl 2():S78-87. PubMed ID: 9831328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
    Wallace JL; McKnight W; Reuter BK; Vergnolle N
    Gastroenterology; 2000 Sep; 119(3):706-14. PubMed ID: 10982765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury.
    Tsugawa K; Hashizume M; Migou S; Kishihara F; Kawanaka H; Tomikawa M; Sugimachi K
    J Gastroenterol Hepatol; 1999 Jul; 14(7):642-51. PubMed ID: 10440208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
    Bjarnason I; Thjodleifsson B
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New directions in cyclooxygenase research and their implications for NSAID-gastropathy.
    Flower RJ
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():23-7. PubMed ID: 9032578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach.
    Ukawa H; Yamakuni H; Kato S; Takeuchi K
    Dig Dis Sci; 1998 Sep; 43(9):2003-11. PubMed ID: 9753266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase inhibition and thrombogenicity.
    Catella-Lawson F; Crofford LJ
    Am J Med; 2001 Feb; 110 Suppl 3A():28S-32S. PubMed ID: 11173047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions.
    Tomisato W; Tsutsumi S; Hoshino T; Hwang HJ; Mio M; Tsuchiya T; Mizushima T
    Biochem Pharmacol; 2004 Feb; 67(3):575-85. PubMed ID: 15037209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.